Prevention of deep venous thrombosis and pulmonary embolism following stroke: A systematic review of published articles

European Journal of Neurology

Volumn 14, Issue 1, 2007, Pages 21-32

  Andre C ^a   De Freitas, G R ^a   Fukujima, M M ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clinical trials; Deep venous thrombosis; Prevention; Pulmonary embolism; Stroke; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CY 222; DALTEPARIN; DANAPAROID; DEXTRAN; DIPYRIDAMOLE; EMBOLEX; ENOXAPARIN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN; WARFARIN;

BLEEDING; BRAIN INFARCTION; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COMPRESSION THERAPY; DATA BASE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WALKING DIFFICULTY;

CEREBROVASCULAR ACCIDENT; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 33846131257     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01536.x     Document Type: Review

References (59)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
2. Sandercock PAG, van der Belt A, Lindley R, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. Journal of Neurology, Neurosurgery and Psychiatry 1993; 56: 17-25.
3. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine 1995; 333: 1588-1593.
4. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
6. Hommel M, for the FISS bis Investigators Group. Fraxiparine in acute ischemic stroke (FISS). Cerebrovascular Diseases 1998; 8(Suppl. 4): 19 (abstract).
7. Adams HP, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Heart Association. Stroke 2003; 34: 1056-1083.
8. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483S-512S.
9. Adams H, Adams R, Del Zoppo G, Goldstein LB, Stroke Council of the American Heart Association; American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update, a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.
10. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]; Section 6. http://www.cochrane. org/resources/handbook/hbook.htm (accessed 31st March 2005), 2005.
11. Lacut K, Bressollette L, Le Gal G, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 2005; 65: 865-869.
12. Prasad BK, Banerjee AK, Howard H. Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. Age and Ageing 1982; 11: 42-44.
13. Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. Neurology 1998; 50: 1683-1688.
14. Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. The Quarterly Journal of Medicine 2000; 93: 359-364.
15. Mazzone C, Chiodo Grandi F, Sandercock P, Miccio M, Salvi R. Physical Methods for Preventing Deep Vein Thrombosis in Stroke (Cochrane Review). The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2004.
16. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke. A prospective study using magnetic resonance direct thrombus imaging. Stroke 2004; 35: 2320-2326.
17. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1997; 2: 800-801.
18. Cz̀echanowski B, Heinrich F. Prophylaxe venöser thrombosen bei frischem ischämischem zerebrovaskulaärem insult. Doppelblindstudie mit Heparin-Dihydergot. Deutsche Medizinische Wochenschrift 1981; 106: 1254-1260.
19. Marti-Vilalta JL, Marco-Igual M. Profilaxis de las complicaciones tromboembólicas en los enfermos vasculares cerebrales. Estudio prospectivo de 124 casos. Medicina Clinica 1982; 79: 400-402.
20. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing 1986; 15: 84-88.
21. Dickman U, Voth E, Schicha H, Henze T, Prange H, Emrich D. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage. Klinische Wochenschrift 1988; 66: 1182-1183.
22. Wasay M, Khan S, Zaki S, Khaleani BA. A non-randomized evaluation of safety and efficacy of heparin for prevention of deep venous thrombosis in patients with intracerebral hemorrhage. Neurology 2003; 60(Suppl. 1): A231.
23. Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry 1991; 54: 466-467.
24. Turpie AGG, Hirsh J, Jay RM, et al. Double-blind randomised trial of ORG 10172 low-molecular-weight heparinoid in the prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; 7: 523-526.
25. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH. Prophylaxis of deep-vein thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989; 19: 245-250.
26. Elias A, Milandre L, Lagrange G, et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne 1990; 11: 95-98.
27. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis 1990; 16(Suppl.): 25-33.
28. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. A randomized controlled trial. JAMA 1998; 279: 1265-1272.
29. Bath PMW, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke. A meta-analysis of randomized controlled trials. Stroke 2000; 31: 1770-1778.
30. Hossman V, Loettgen J, Auel H, Bewermeyer H, Heiss WD. Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomized double-blind study. Haemostasis 1986; 16: 54 (abstract).
31. Turpie AG, Gent M, Côte R, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Annals of Internal Medicine 1992; 117: 353-357.
32. Dumas R, Woitinas F, Kutnowski M, et al. A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age and Ageing 1994; 23: 512-516.
33. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs. heparin for prevention of deepvein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurologica Scandinavica 2002; 106: 84-92.
34. Counsell C, Sandercock P. Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischaemic Stroke. The Cochrane Database of Systematic Reviews. The Cochrane Library, Copyright 2004, The Cochrane Collaboration Vol. 3. Chichester, UK: John Wiley & Sons, Ltd, 2004.
35. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31: 1240-1249.
36. Cameron EW, Sachdev D, Gishen P, Martin JF. Liquid crystal thermography as a screening test for deep vein thrombosis in patients with cerebral infarction. European Journal of Clinical Investigation 1991; 21: 548-550.
37. Harvey RL, Lovell LL, Belanger N, Roth EJ. The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation: a historical cohort study. Archives of Physical Medicine and Rehabilitation 2004; 85: 1070-1075.
38. Berge E, Abdelnoor M, Nakstad PH, Sandset PM, on behalf of the HAEST Study Group. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet 2000; 355: 1205-1210.
39. Bath PMW, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-710.
40. Leonardi-Bee J, Bath F, Bath P. Comparison of low molecular weight heparin with aspirin in the treatment of acute ischaemic stroke: a systematic review. Cerebrovascular Diseases 2001; 11(Suppl. 4): 75 (abstract).
41. Mellbring G, Strand T, Eriksson S. Venous thromboembolism after cerebral infarction and the prophylactic effect of Dextran 40. Acta Medica Scandinavica 1986; 220: 425-429.
42. Ginsberg JS, Bates SM, Oczkowski W, et al. Low-dose warfarin in rehabilitating stroke survivors. Thrombosis Research 2002; 107: 287-290.
43. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988; 39: 505-513.
44. Cramer SC, Rordorf G, Maki JH, et al. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli From Large Veins in Ischemic Stroke (PELVIS) Study. Stroke 2004; 35: 46-50.
45. Marchuk G, Teasle R. Clinically symptomatic deep venous thromboembolism in a stroke population. Ykpanñ Meununhcknn Xyphaj 2000; 2: 86-88.
46. Sioson ER, Crowe WE, Dawson NV. Occult proximal deep vein thrombosis: its prevalence among patients admitted to a rehabilitation hospital. Archives of Physical Medicine and Rehabilitation 1988; 69: 183-185.
47. Pambianco G, Orchard T, Landau P. Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation 1995; 76: 324-330.
48. Cohen D, Lewis S, Sandercock P. Frequency of death, dependency and pulmonary embolism after haemorrhagic stroke. Cerebrovascular Diseases 2000; 10(Suppl. 2): 52 (abstract).
49. Roth EJ, Lovell L, Harvey RL, Heinemann AW, Semik P, Diaz S. Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke 2001; 32: 523-529.
50. Gregory PC, Kuhlemeier KV. Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke. American Journal of Physical Medicine and Rehabilitation 2003; 82: 364-369.
51. Bosson JL, Labarere J, Sevestre MA, et al. Deep-vein thrombosis in elderly patients hospitalized in subacute care facilities. A multicenter, cross-sectional study of risk factors, prophylaxis and prevalence. Archives of Internal Medicine 2003; 163: 2613-2618.
52. Kelly J, Hunt BJ, Lewis RR, et al. Dehydration and venous thromboembolism after acute stroke. The Quarterly Journal of Medicine 2004; 97: 293-296.
53. Davis SM, Donnan GA. Effective prophylaxis for deep venous thrombosis after stroke: both low-dose anticoagulation and stockings for most cases. Stroke 2004; 35: 2910.
54. Dennis MS. Effective prophylaxis for deep venous thrombosis after stroke: low-dose anticoagulation rather than stockings alone: against. Stroke 2004; 35: 2912-2913.
55. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Annals of Internal Medicine 1997; 126: 376-380.
56. Berge E, Sandercock P. Anticoagulants Versus Antiplatelet Agents for Acute Ischaemic Stroke (Cochrane Review). The Cochrane Library, Issue 2. Oxford: Update Software, 2005.
57. Mezzadri JJ, Goland J, Ottino CA, Basso A. Control perioperatorio del tratamiento anticoagulante en pacientes con hemorragia intracraneana/ perioperative management of anticoagulant treatment in patients with intracranial hemorrhage. Revista Do Hospital Das Clinicas 1995; 9: 13-17.
58. Dunbabin DW. Prophylaxis against deep venous thrombosis and pulmonary embolism in patients with stroke. Vascular Medicine 1996; 1: 207-212.
59. Schneider D. Thrombosis prophylaxis after stroke. Deutsche Medizinische Wochenschrift 1998; 123: 783.